The Equipoise Between the Treatment of Glioblastoma and the Risk of Secondary Acute Myelogenous Leukemia: An Illustrative Case Report

We present a case report of a 56-year-old woman who was diagnosed with biopsy-proven left thalamic glioblastoma multiforme (GBM). She was treated with standard concurrent chemotherapy and radiation, as well as a 2-year period of adjuvant temozolomide. She relapsed 2 ½ years after starting her initial therapy and was treated with bevacizumab and lomustine, but she relapsed. She was then placed on a phase 1/2 clinical trial that included KHK2455 and mogamulizumab-kpkc individually and in combination for almost 4 years. She had a rapid demise due to the development of a neutropenic pneumonia and treatment-induced acute myeloid leukemia (AML) and elected for hospice care.

[1]  V. Zagonel,et al.  Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study , 2021, Cancers.

[2]  M. Weller,et al.  Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma , 2020, JAMA oncology.

[3]  C. Balañà,et al.  A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01). , 2020, Neuro-oncology.

[4]  D. Hong,et al.  First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors. , 2018 .

[5]  B. Devnani,et al.  Comparative Study of Adjuvant Temozolomide Six Cycles Versus Extended 12 Cycles in Newly Diagnosed Glioblastoma Multiforme. , 2017, Journal of clinical and diagnostic research : JCDR.

[6]  G. Reifenberger,et al.  Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma , 2017, Neurology.

[7]  J. Reijneveld,et al.  Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis , 2016, Journal of Neuro-Oncology.

[8]  Thomas C. Chen,et al.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. , 2015, JAMA.

[9]  K. Aldape,et al.  A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[10]  K. Hoang-Xuan,et al.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.

[11]  Y. Miyakita,et al.  Secondary hematological malignancies associated with temozolomide in patients with glioma. , 2013, Neuro-oncology.

[12]  M. Khasraw,et al.  Long-term use of temozolomide: Could you use temozolomide safely for life in gliomas? , 2009, Journal of Clinical Neuroscience.

[13]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[14]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[15]  J. Gockerman,et al.  Acute leukemia following treatment of malignant glioma , 1998, Journal of Neuro-Oncology.

[16]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.